Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

138 results about "Rna targeting" patented technology

Taq DNA Polymerase Variants with Increased Reverse Transcriptase Activity

Taq DNA polymerase mutants exhibiting reverse transcriptase activity compared to wild type polymerase were engineered, characterized, and selected via polymerase chain reactions visualized via electrophoresis on agarose gels. Initial screening was followed up with probe-based qualitative, real-time PCR (qPCR) with a typical reverse transcription cycling protocol to detect specified ribonucleic acid (RNA) target sequences. The engineered variants can render robust cDNA from RNA target substrates and amplify that cDNA under standard reaction conditions without the assistance of added reverse transcriptase enzymes.
Owner:ABCLONAL SCIENCE INC

SiRNA for simultaneously inhibiting expression of two target genes, medicine and application of siRNA and medicine

ActiveCN119040325AImprove silence abilityReduce off-target activityOrganic active ingredientsSpecial deliveryDiseaseSubtilisin
The invention relates to a dual-targeting s-RNA agent, which comprises two different s-RNAs targeting two different genes or pharmaceutically acceptable salts thereof, the two different s-RNAs or salts thereof are connected through pharmaceutically acceptable ligands, the s-RNAs are dsRNAs formed by positive-sense strands and antisense strands, and the s-RNAs are dsRNAs formed by positive-sense strands and antisense strands. The two different genes are selected from two of angiotensinogen (AGT), proprotein convertase subtilisin 9 (PCSK9) and human angiopoietin-like protein 3 (ANGPTL3). The invention provides application of the dual-targeting s iRNA agent in preparation of drugs for preventing or treating diseases related to hypertension or / and lipid disorder. The double-targeting s iRNA agent can effectively inhibit expression of two target genes in vivo at the same time, and has the advantages of being high in mutual non-antagonistic activity and high in safety. The invention also provides the s iRNA of the corresponding gene of the dual-targeting s iRNA agent and application of the s iRNA to prevention or treatment of diseases related to hypertension or / and lipid disorder.
Owner:GUANGZHOU BEBETTER MEDICINE TECH CO LTD

Target segment and double-stranded RNA for preventing and treating tomato brown crinkled fruit virus in tobacco and application of target segment and double-stranded RNA

The invention discloses a target segment for preventing and treating tomato brown fruit wrinkling virus in tobacco, double-stranded RNA (Ribonucleic Acid) and application of the target segment and the double-stranded RNA. Wherein the nucleotide sequence of the target segment is as shown in SEQ ID NO.3, or a sequence which is as shown in SEQ ID NO.3, has at least 90% of homology and has coded amino acid as shown in SEQ ID NO.4 is substituted. The invention also discloses a double-stranded RNA of a targeted interference target section, and the double-stranded RNA can significantly inhibit the proliferation of the tomato brown crinkled fruit virus in tobacco by injecting or smearing tobacco leaves, so that the double-stranded RNA can be effectively applied to prevention and control of tobacco diseases caused by the tomato brown crinkled fruit virus. The method for preventing and controlling the tomato brown crinkled fruit virus in the tobacco by using the double-stranded RNA is safe, harmless and efficient, and provides a new path for preventing and controlling plant virus diseases by using RNAi (Ribonucleic Acid Interference).
Owner:NINGBO UNIV

Plant-derived Argonaute protein and application thereof

The invention discloses a plant-derived Argonaute protein and application thereof, and belongs to the technical field of gene editing and detection. The plant-derived Argonaute protein is specifically a protein with an amino acid sequence as shown in SEQ ID NO.1, or a protein which has at least 80% of homology with the amino acid sequence as shown in SEQ ID NO.1 and has corresponding functions; the Argonaute protein specifically cleaves target nucleic acid under mediation of guide nucleic acid, the guide nucleic acid is guide DNA or guide RNA, and the target nucleic acid is a DNA target or an RNA target. Compared with the reported eukaryotic Argonaute protein derived from unicellular organisms, the Argonaute protein used in the invention is derived from rice, has greater application potential in the field of animal and plant gene editing, not only has RNase activity and activity of cutting a DNA target by utilizing guide RNA, but also can cut the DNA target by utilizing guide DNA, so that the scheme of the invention has good application prospect.
Owner:HUBEI UNIV

Double-stranded RNA targeting coagulation factor xi

Provided are a double-stranded RNA targeting coagulation factor XI, a pharmaceutically acceptable salt thereof, or a ligand conjugate thereof。 Further provided are a pharmaceutical composition comprising the double-stranded RNA, the pharmaceutically acceptable salt thereof, or the ligand conjugate thereof, as well as a therapeutic use of the double-stranded RNA, the pharmaceutically acceptable salt thereof, or the ligand conjugate thereof.
Owner:CHIA TAI TIANQING PHARMA GRP CO LTD

Preparation method of RNA (Ribonucleic Acid) targeted photosensitizer and application of RNA targeted photosensitizer in anti-tumor treatment

The invention discloses a preparation method of an RNA targeted photosensitizer and an application of the RNA targeted photosensitizer in anti-tumor treatment, and belongs to the technical field of fine chemical engineering. The photosensitizer is modified on the basis of a fluorescent molecule parent, and the RNA targeted photosensitizer is constructed. The photosensitizer disclosed by the invention can be self-assembled into nanoparticles in an aqueous solution, shows good RNA targeting, effectively generates reactive oxygen species through I-type and II-type mechanisms, and shows excellent performance in the aspects of long-term fluorescence imaging in tumor cells and anti-tumor treatment in normal-oxygen and hypoxic environments; the fluorescence of the photosensitizer Se-cy is enhanced by about 230 times after RNA is added, and the fluorescence duration can be kept as long as 40 hours in in-vitro cells; and the fluorescent label can be kept for 4 days in vivo, shows excellent fluorescent durability, and has a remarkable anti-tumor effect on tumor-bearing mice.
Owner:DALIAN UNIV OF TECH

Methods for detecting RNA binding protein complexes

The present disclosure relates to methods of identifying RNA targets of RNA binding proteins. In aspects, the disclosure relates to a method of identifying RNA molecules bound by RNA binding proteins. Some embodiments of the present disclosure relate to a method that can definitively identify direct RNA-target interactions with targeted proteins without the requirement for immunoprecipitation or gel extraction. In some embodiments, the method may include combining multiple antibodies in the same sample.
Owner:ECLIPSE BIOINNOVATIONS INC

Advanced RNA targeting (arnatar) for angiotensinogen

Disclosed herein are Advanced RNA Targeting (ARNATAR) dsRNA compounds targeting angiotensinogen (AGT). Such compounds are useful in methods for reducing expression of AGT and for therapeutically treating RAAS associated diseases, disorders and / or conditions, or symptoms thereof in a subject.
Owner:ARNATAR THERAPEUTICS INC

System and method for predicting binding affinity of small molecules to RNA targets

PCT designated stage expiredWO2025022226A1BiostatisticsProteomicsRNA SequenceRNA - Ribonucleic acid
The present disclosure is directed to a system 100 and a method 300 for predicting binding affinity of small molecules to Ribo-Nucleic Acid (RNA) targets The method comprises of receiving an input from a user, comprising a sequence of an RNA target, information related to a small molecule and a sub-type of the RNA target. The method further comprises of predicting a binding affinity of the small molecule to the RNA target of the sub-type, using a prediction model. Generating the prediction model comprises of, obtaining a plurality of RNA sequence based features for a plurality of sub-types of a plurality of RNA targets, and a plurality of small molecule features for a plurality of small molecules. Generating the prediction model further comprises of identifying a plurality of non-correlated features from the plurality of RNA sequence based features and the plurality of small molecule features and generating a final feature combination from the plurality of non- correlated features for each sub-type of the plurality of sub-types of the plurality of RNA targets based on a quasi-binding affinity of each of the plurality of small molecules with each sub-type of the plurality of sub-types of the plurality of RNA targets. The final feature combination is used to generate the prediction model.
Owner:INDIAN INST OF TECH MADRAS

Target section and double-stranded RNA for preventing and controlling propagation of tomato brown crinkled fruit virus through tomato seeds and application of target section and double-stranded RNA

The invention discloses a target segment and double-stranded RNA for preventing and controlling propagation of tomato brown crinkled fruit virus through tomato seeds and application of the target segment and the double-stranded RNA. Wherein the nucleotide sequence of the target segment is as shown in SEQ ID NO.3, or a sequence which is as shown in SEQ ID NO.3, has at least 90% of homology and has coded amino acid as shown in SEQ ID NO.4 is substituted. The invention further discloses double-stranded RNA of the target interference target section, the double-stranded RNA is used for single isolation treatment or batch treatment of germinated tomato seeds, and the infection rate of the tomato brown crinkled fruit virus on germinated tomato seedlings can be effectively reduced under the condition that the germination rate of the tomato seeds is not affected. The method for preventing and controlling propagation of the tomato brown crinkled fruit virus through the tomato seeds by using the double-stranded RNA is safe and harmless, and has a good application prospect.
Owner:NINGBO UNIV

Advanced RNA targeting (arnatar) for angiotensinogen

Disclosed herein are Advanced RNA Targeting (ARNATAR) dsRNA compounds targeting angiotensinogen (AGT), Such compounds are useful in methods for reducing expression of A GT and for therapeutically treating RAAS associated diseases, disorders and / or conditions, or symptoms thereof in a subject.
Owner:ARNATAR THERAPEUTICS INC

Advanced RNA targeting (arnatar) for inhbe

PCT designated stageWO2026064538A2DNA/RNA fragmentationDiseaseTherapeutic treatment
Disclosed herein are Advanced RNA Targeting (ARNATAR) dsRNA compounds targeting Inhibin βE (INHBE). Such compounds are useful in methods for reducing expression of INHBE and for therapeutically treating INHBE associated diseases, disorders and / or conditions, or symptoms thereof in a subject.
Owner:ARNATAR THERAPEUTICS INC

Inhibitory RNA targeting huntingtin expression

PCT designated stage expiredWO2025006937A2Organic active ingredientsNervous disorderPrimary MicroRNAPolynucleotide
The present invention features RNA polynucleotide constructs comprising sequences targeting Huntingtin mRNA, polynucleotide constructs comprising a sequence encoding for such RNA constructs, and primary microRNA scaffolds. Constructs comprising sequences targeting Huntingtin mRNA and / or encoding for sequences targeting Huntingtin mRNA can be used, for example, for inhibiting mutant HTT expression and / or treating Huntington disease.
Owner:SPARK THERAPEUTICS INC +1

Bioluminescent probes for visualizing RNA dynamics

A complete understanding of RNA biology requires methods for tracking transcripts in vivo. Common strategies rely on fluorogenic probes that are limited in sensitivity, dynamic range, and depth of interrogation, owing to their need for excitation light and tissue autofluorescence. To overcome these challenges, a bioluminescent platform for serial imaging of RNAs is described herein. Small RNA tags were engineered to recruit light-emitting luciferase fragments (termed RNA lanterns) upon transcription. Robust photon production was observed for RNA targets both in cells and in live animals. Importantly, only a single copy of the tag was necessary for sensitive detection, in sharp contrast to fluorescent platforms requiring multiple repeats. Overall, this work provides a foundational platform for visualizing RNA dynamics from the micro to the macro scale.
Owner:RGT UNIV OF CALIFORNIA

Application of neuropeptide gene CpILP6 in relieving diapause of codling moth

The invention relates to the technical field of agricultural biology, in particular to application of a neuropeptide gene CpILP6 in relieving diapause of codling moths. After siRNA is microinjected to silence CpILP6 in a targeted manner, the diapause state of CpILP6 is changed and tends to a normal development phenotype; the research result of the invention provides a theoretical basis for defining the regulation function of the neuropeptide gene CpILP6 in the diapause induction and maintenance process of codling moth.
Owner:INST OF PLANT PROTECTION CHINESE ACAD OF AGRI SCI

Isolated CAS13 proteins, gene editing system based thereon, and use thereof

The present application relates to isolated novel CRISPR / Cas13 proteins, a gene editing systems based thereon, and a method for using said proteins for RNA level gene editing. Provided are non-naturally occurring or engineered RNA targeting systems, and said systems each have a novel Cas13 effector protein that targets RNA and at least one type of guide molecule.
Owner:BEIJING INST FOR STEM CELL & REGENERATIVE MEDICINE +1

Multiplexed rna modulation platform for primary immune cell engineering

The present disclosure provides a universal and multifunctional platform for transcriptome modulation that utilizes RNA-guided RNA targeting activity that binds to a VI-D type CRISPR effector with RNA-guided RNA endonuclease activity that expresses a guide array of a plurality of guide RNAs. The system can be used for quantitative, reversible and large-scale multiplex gene knock-down in primary human T cells, and multiplex inhibition of consumption related genes in T cells. The system can be used for enhancing the anti-tumor activity of dysfunctional CAR T cells.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Space-time resolution single cell transcriptome detection method

The invention discloses a time-space resolution single cell transcriptome detection method, which comprises the following steps: firstly, carrying out specific marking on RNA newly generated by cells within a specific time by using a metabolism marking technology so as to ensure that new RNA molecules can be accurately identified and tracked; then, signal amplification of a new RNA target is realized through an adjacent rolling circle amplification (PLA-RCA) technology, and the detection sensitivity is improved; and finally, realizing high-throughput analysis on the newborn RNA by using an in-situ fluorescence sequencing technology, and carrying out accurate space positioning and quantification on the newborn RNA in the single cell by the step. Through the method, time and space resolution analysis can be provided for a single cell transcriptome, so that analysis of complex biological processes such as cell differentiation, disease occurrence and cell function response is facilitated; moreover, the method has important significance for revealing a molecular mechanism in a cell biological process, and provides a new visual angle and tool for disease diagnosis and treatment.
Owner:XIAMEN UNIV

Artificial intelligence (AI)-informed noncoding RNA targeting

Disclosed are methods, systems, and computer readable media for predicting interactions for RNA sequences, including long noncoding RNA (IncRNA), which can be used, for example, as biomarkers. In an example method of predicting one or more binding sites between a ribonucleotide (RNA) sequence and a RNA binding protein, the method includes at a computing platform including at least one processor and memory: preparing sequence data for a plurality of overlapping RNA segments derived from a target sequence; inputting the sequence data for the plurality of overlapping RNA segments into a machine learning model trained to predict a probability of an interaction between a RNA sequence and a RNA binding protein occurring in a RNA sequence; outputting from the machine learning model one or more segments in the sequence data for the plurality of overlapping RNA segments falling above a probability threshold indicative of a region of interaction between a RNA sequence and a RNA binding protein; and predicting one or more binding sites between a RNA sequence and a RNA binding protein in the sequence data for the plurality of overlapping RNA segments derived from the target sequence based on the output from the model.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL

Treatment of cardiovascular disease

This disclosure relates to a nucleic acid comprising a double stranded RNA molecule comprising sense and antisense strands and further comprising a single stranded DNA molecule covalently linked to at least the 5′ end of either the sense or antisense RNA part of the molecule wherein the double stranded inhibitory RNA targets genes associated with cardiovascular disease in the treatment hypercholesterolemia and diseases associated with hypercholesterolemia such as cardiovascular disease.
Owner:ARGONAUTE RNA LTD

A method for constructing an animal model of LncRNA XIST gene knock-in based on RNA targeting binding sites

ActiveCN114783509BSolve the problem of high miss ratePracticalNucleic acid vectorProteomicsPhysiologyBinding site
This invention discloses a method for constructing an LncRNA XIST gene knock-in animal model based on RNA targeting binding sites. The method includes bioinformatics analysis of the XIST gene and the mmu-miR-140-5p targeting binding site in the seventh exon of the XIST gene; in vitro experiments confirming the targeting binding site of the XIST gene and mmu-miR-140-5p in the bioinformatics analysis; construction of an sgRNA vector targeting the seventh exon of the mouse XIST gene containing the targeting binding site; in vitro transcription of the sgRNA; acquisition and identification of F0 generation mice; acquisition and identification of F1 generation heterozygous mice; and the acquisition of homozygous offspring. This method solves the problem of high off-target rates caused by excessively long fragments during the knock-in of XIST genes (up to 17.9 kb with seven exons) using CRISPR / Cas9.
Owner:AFFILIATED HOSPITAL OF GUILIN MEDICAL UNIV

Decreasing the intrinsically disordered protein alpha-synuclein's levels by targeting its structured mRNA with a ribonuclease targeting chimera

PCT designated stage expiredWO2024238369A1Nervous disorderOrganic chemistryDiseasePharmaceutical medicine
The present disclosure provides compounds of the formulae herein (e.g., Formula (I)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof, which bind and / or effect degradation of an RNA target. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, and methods of treating or preventing diseases by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, or pharmaceutical compositions thereof.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Advanced RNA targeting (ARNATAR)

Disclosed herein are advanced RNA targeting (ARNATAR) oligomeric compounds, which are elaborately designed compounds, for the inhibition of gene expression by the RISC pathway. Such compounds are useful in methods for reducing the expression of certain genes, where many genes are associated with a variety of diseases and disorders.
Owner:ARNATAR THERAPEUTICS INC

Target validation and profiling of the RNA targets of small molecules

A method for the precise cellular destruction of an oncogenic non-coding RNA with a RNA-binding small molecule conjugated with bleomycin A5 is described. The method affords reversal of phenotype. Bleomycin A5 was coupled to an RNA-binding molecule that selectively binds the microRNA-96 hairpin precursor (pri-miR-96). By coupling of bleomycin A5's free amine to the RNA-binding molecule, its affinity for binding to pri-miR-96 is >100-fold stronger than to DNA. The conjugate compound selectively cleaves pri-miR-96 in triple negative breast cancer (TNBC) cells. Selective cleavage of pri-miR-96 enhances expression of FOXO1 protein, a pro-apoptotic transcription factor that miR-96 silences, and triggers apoptosis in TNBC cells. No effects were observed in healthy breast epithelial cells. This method provides programmable control for targeting RNA through the selection of an RNA-binding molecule / bleomycin A5 conjugate and provides a facile method of mapping the cellular binding sites of an RNA-binding molecule.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

RNA (Ribonucleic Acid) target region enrichment method based on annular probe

The invention discloses an RNA (Ribonucleic Acid) target region enrichment method based on a circular probe, and belongs to the technical field of biomolecule detection and gene sequencing. The method comprises the following steps: designing an annular probe containing an anchoring sequence, a UMI sequence and a universal primer sequence (at least one anchoring sequence 5'end is phosphorylated and modified); the method comprises the following steps: hybridizing a probe with target RNA (Ribonucleic Acid), enriching a hybridization compound through oligo d (T) magnetic beads, cyclizing the probe through DNA ligase, and carrying out PCR (Polymerase Chain Reaction) amplification to obtain an enriched product. Reverse transcription and extension steps are not needed, a solid-phase substrate is not needed, the experimental process is simplified, and the operation time is shortened; through combination of specific probe design and magnetic bead enrichment, high-selectivity enrichment of target RNA is realized, the method is especially suitable for differential expression analysis of samples with low expression quantity, and the template recovery rate and the effective data proportion are effectively improved.
Owner:SHANGHAI YOUJIA MEDICAL TECH CO LTD

Compositions comprising nanoparticles for targeted delivery and methods of using the same

PCT designated stage expiredWO2025049355A1Powder deliverySpecial deliveryDiseaseNanoparticle
Disclosed herein are compositions comprising nanoparticles designed for CRISPR / Cas13 RNA targeting systems, specifically aimed at targeting poorly druggable, disease-driving genes in prostate cancer and COVID-19, and methods of use thereof.
Owner:DUKE UNIV +2

Use of lncRNA XR_595534.2 in preparation of medicine for treatment or prevention of chronic pain

The present invention provides use of lncRNA XR_595534.2 in the preparation of a medicine for the treatment or prevention of chronic pain. In the present invention, trigeminal neuralgia induced by chronic constriction injury of infraorbital nerve in rats is used as a pain model. A specifically and differentially highly expressed long-chain non-coding RNA gene lncRNA XR_595534.2 is screened in the model. An interfering RNA targeting lncRNA XR_595534.2 is provided for disease treatment. The present invention discovers for the first time that lncRNA XR_595534.2, which is specifically and differentially highly expressed in a pain model, has significantly reduced expression by stereotactic injection of an interfering RNA to relieve the pain behavior, and is useful in the preparation of a medicine for the treatment or prevention of trigeminal neuralgia, neuropathic pain, migraine and cancer pain where lncRNA-XR595534.2 is a target.
Owner:SUZHOU UNIV

Assays to measure nucleic acid-modifying enzyme activity

The application discloses a multiplex method for measuring nucleic acid modification enzyme activity and screening one or more variable elements of enzymatic reaction.The method includes: (i) providing a polynucleotide construct library encoding DNA / RNA target site and variable element to be tested such as nucleic acid modification enzyme variant, (ii) partitioning a single copy of the polynucleotide construct with in vitro transcription and translation (IVVT) reagent, (iii) allowing the IVVT reaction of nucleic acid modification enzyme and DNA / RNA target site to be expressed in each compartment, (iv) depending on the functionality of the nucleic acid modification enzyme encoded, single polynucleotide construct / RNA target is cracked, remains intact or otherwise modified, and (v) by sequencing to cracked, complete or modified polynucleotide construct / RNA target quantification, so as to directly identify the enzymatic activity related to each variable element and to the enzymatic activity quantification.Particularly, nucleic acid modification enzyme is CRISPR associated protein (Cas).
Owner:AGENCY FOR SCI TECH & RES

In situ nucleic acid analysis using probe pair ligation

In one aspect, compositions are provided for the simultaneous in situ quantification and localization of RNA sequences with subcellular precision are utilized in the methods. In particular, specific hybridization of at least one probe set in a sample is followed by in situ ligation, which locks specifically circularized probe set around an RNA target sequence. Rolling circle amplification followed by fluorescently labeled detector probe hybridization, enables simultaneous in situ quantification and localization of RNA sequences with subcellular precision.
Owner:JOHNS HOPKINS UNIVERSITY